Voriconazole Therapeutic Drug Monitoring is Necessary for Children with Invasive Fungal Infection.
- Author:
Hyun Mi KANG
;
Soo Young KANG
;
Eun Young CHO
;
Kyung Sang YU
;
Ji Won LEE
;
Hyoung Jin KANG
;
Kyung Duk PARK
;
Hee Young SHIN
;
Hyo Seop AHN
;
Hyunju LEE
;
Eun Hwa CHOI
;
Hoan Jong LEE
- Publication Type:Original Article
- Keywords:
Therapeutic drug monitoring;
Voriconazole;
Child;
Invasive aspergillosis;
Invasive fungal infection
- MeSH:
Alanine Transaminase;
Aspartate Aminotransferases;
Child*;
Drug Monitoring*;
Humans;
Retrospective Studies
- From:Korean Journal of Pediatric Infectious Diseases
2014;21(1):9-21
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To determine the clinical significance of voriconazole therapeutic drug monitoring (TDM) in the pediatric population. METHODS: Twenty-eight patients with invasive fungal infections administered with voriconazole from July 2010 to June 2012 were investigated retrospectively. Fourteen received TDM, and 143 trough concentrations were analyzed. All 28 patients were assessed for adverse events and treatment response six weeks into treatment, and at the end. RESULTS: Out of 143 samples, 53.1% were within therapeutic range (1.0-5.5 mg/L). Patients administered with the same loading (6 mg/kg/dose) and maintenance (4 mg/kg/dose) dosages prior to initial TDM showed highly variable drug levels. Adverse events occurred in 9 of 14 patients (64.3%) in both the TDM and non-TDM group. In the TDM group, voriconazole-related encephalopathy (n=2, 14.3%) and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevation (n=8, 57.1%) occurred with serum levels in the toxic range (>5.5 mg/L), whereas blurred-vision (n=2, 14.3%) occurred within the therapeutic range (1.18 mg/L and 3.9 mg/L). The frequency of voriconazole discontinuation due to adverse events was lower in the TDM group (0.0% vs. 18.2%, P=0.481). Overall, 57.2% of the patients in the TDM group versus 14.3% in the non-TDM group showed clinical response after 6 weeks (P=0.055), whereas 21.4% in the TDM group versus 14.3% in the non-TDM group showed response at final outcome (P=0.664). In the TDM group, >67.0% of the serum levels were within therapeutic range for the first 6 weeks; however 45.5% were within therapeutic range for the entire duration. CONCLUSION: Routine TDM is recommended for optimizing the therapeutic effects of voriconazole.
